RxDoctor Payments Data

Daniel Glatt, MD

Internal Medicine · Burlingame, CANPI 1649228917

Payments from drug & device makers

$44,692in general payments, 2019–2025

Across 773 payments — averaging $57.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$16K
  • Indivior Inc.$10K
  • Biodelivery Sciences International, Inc.$6K
  • AbbVie$2K
  • Novo Nordisk$957
  • Pfizer$936
  • plus $9K from 54 others

What the payments were for

  • Speaking & faculty fees$27,28561%
  • Travel & lodging$2,0965%
  • Food & beverage$15,23134%
  • Education$810%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alkermes, Inc.43$16,451
Indivior Inc.62$9,568
Biodelivery Sciences International, Inc.17$5,965
AbbVie(2 entities)110$1,970
Novo Nordisk53$957
Pfizer45$936
Collegium Pharmaceutical, Inc.51$871
Boehringer Ingelheim39$762
Lilly USA, LLC27$534
AstraZeneca22$491
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC24$479
Takeda Pharmaceuticals U.S.A., Inc.23$384
Sunovion Pharmaceuticals Inc.31$327
Astellas Pharma US Inc17$320
Otsuka America Pharmaceutical, Inc.17$316
Merck14$269
Amgen(2 entities)10$239
Johnson & Johnson11$228
Redhill Biopharma Inc.12$216
GSK8$212
Teva Pharmaceuticals USA, Inc.9$210
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)10$209
Idorsia Pharmaceuticals US Inc8$164
Lundbeck LLC7$163
Seqirus USA Inc8$149
Axsome Therapeutics, Inc.5$146
Bausch Health US, LLC6$132
Esperion Therapeutics, Inc.5$125
Eisai Inc.7$120
Novartis6$120
Orexo US, Inc.6$101
Verity Pharmaceuticals Inc.5$100
Biohaven Pharmaceutical Holding Company Ltd.4$96
Vertex1$95
Edwards Lifesciences3$93
Biohaven Pharmaceuticals, Inc.3$93
E.r. Squibb & Sons, L.L.C.4$88
Tonix Medicines, Inc.1$84
Braeburn Inc.3$84
Medicure Pharma Inc.1$63
Kowa Pharmaceuticals America, Inc.3$60
Vanda Pharmaceuticals Inc.2$53
Exact Sciences2$52
Covis Pharma GmbH1$50
Boston Scientific2$47
Bayer2$45
Assertio Therapeutics, Inc.3$44
Sanofi-aventis U.S. LLC2$37
Forte Bio-pharma LLC1$37
Hikma Pharmaceuticals USA2$35
MDD US Operations, LLC2$35
Avanir Pharmaceuticals, Inc.1$31
Phathom Pharmaceuticals, Inc.1$26
Almatica Pharma LLC1$24
Alfasigma USA, Inc.1$23
Jazz Pharmaceuticals Inc.1$23
Neurocrine Biosciences, Inc.1$22
Abbott1$21
Kaleo, Inc.1$21
Ironwood Pharmaceuticals, Inc1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,692 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$217,634
Medicare patients
358
Services billed
2,194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl156$273,592
RybelsusSemaglutide73$99,793
NucyntaTapentadol Hcl70$88,813
Nucynta ErTapentadol Hcl45$82,175
JardianceEmpagliflozin77$80,788
Xtampza ErOxycodone Myristate54$79,505
FarxigaDapagliflozin Propanediol59$51,869
EliquisApixaban58$47,282
Hysingla ErHydrocodone Bitartrate22$37,997
BelbucaBuprenorphine Hcl40$34,832
Fentanyl182$34,129
Hydromorphone ErHydromorphone Hcl59$27,536
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$22,608
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl111$19,810
MyrbetriqMirabegron39$18,129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta, Nucynta Er, Xtampza Er, Belbuca$871$285,325209 claims
Novo NordiskRybelsus, Ozempic$957$115,81288 claims
Boehringer IngelheimJardiance$762$80,78877 claims
AstraZenecaFarxiga$491$51,86959 claims
PfizerEliquis, Premarin$936$50,33871 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine$35$31,490180 claims
AbbVieSavella, Creon$1,970$26,28034 claims
GSKTrelegy Ellipta$212$22,60829 claims
MerckJanumet Xr, Belsomra$269$21,88428 claims
Astellas Pharma US IncMyrbetriq$320$18,12939 claims
Redhill Biopharma Inc.Movantik$216$13,72125 claims
Esperion Therapeutics, Inc.Nexlizet$125$6,22313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Burlingame

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →